290 related articles for article (PubMed ID: 23820108)
1. A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer.
Eustace A; Mani N; Span PN; Irlam JJ; Taylor J; Betts GN; Denley H; Miller CJ; Homer JJ; Rojas AM; Hoskin PJ; Buffa FM; Harris AL; Kaanders JH; West CM
Clin Cancer Res; 2013 Sep; 19(17):4879-88. PubMed ID: 23820108
[TBL] [Abstract][Full Text] [Related]
2. A Gene Signature for Selecting Benefit from Hypoxia Modification of Radiotherapy for High-Risk Bladder Cancer Patients.
Yang L; Taylor J; Eustace A; Irlam JJ; Denley H; Hoskin PJ; Alsner J; Buffa FM; Harris AL; Choudhury A; West CML
Clin Cancer Res; 2017 Aug; 23(16):4761-4768. PubMed ID: 28400426
[No Abstract] [Full Text] [Related]
3. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial.
Janssens GO; Rademakers SE; Terhaard CH; Doornaert PA; Bijl HP; van den Ende P; Chin A; Marres HA; de Bree R; van der Kogel AJ; Hoogsteen IJ; Bussink J; Span PN; Kaanders JH
J Clin Oncol; 2012 May; 30(15):1777-83. PubMed ID: 22508814
[TBL] [Abstract][Full Text] [Related]
4. A miRNA signature predicts benefit from addition of hypoxia-modifying therapy to radiation treatment in invasive bladder cancer.
Khan MT; Irlam-Jones JJ; Pereira RR; Lane B; Valentine HR; Aragaki K; Dyrskjøt L; McConkey DJ; Hoskin PJ; Choudhury A; West CML
Br J Cancer; 2021 Jul; 125(1):85-93. PubMed ID: 33846523
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Outcomes of Radical Radiation Therapy with Hypoxia Modification with Biomarker Discovery for Stratification: 10-Year Update of the BCON (Bladder Carbogen Nicotinamide) Phase 3 Randomized Trial (ISRCTN45938399).
Song YP; Mistry H; Irlam J; Valentine H; Yang L; Lane B; West C; Choudhury A; Hoskin PJ
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1407-1415. PubMed ID: 33689854
[TBL] [Abstract][Full Text] [Related]
6. Computed tomography-based tumour volume as a predictor of outcome in laryngeal cancer: results of the phase 3 ARCON trial.
Janssens GO; van Bockel LW; Doornaert PA; Bijl HP; van den Ende P; de Jong MA; van den Broek GB; Verbist BM; Terhaard CH; Span PN; Kaanders JH
Eur J Cancer; 2014 Apr; 50(6):1112-9. PubMed ID: 24424106
[TBL] [Abstract][Full Text] [Related]
7. Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial.
Eustace A; Irlam JJ; Taylor J; Denley H; Agrawal S; Choudhury A; Ryder D; Ord JJ; Harris AL; Rojas AM; Hoskin PJ; West CM
Radiother Oncol; 2013 Jul; 108(1):40-7. PubMed ID: 23773411
[TBL] [Abstract][Full Text] [Related]
8. Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer.
Kaanders JH; Pop LA; Marres HA; Liefers J; van den Hoogen FJ; van Daal WA; van der Kogel AJ
Radiother Oncol; 1998 Aug; 48(2):115-22. PubMed ID: 9783882
[TBL] [Abstract][Full Text] [Related]
9. Acute toxicity profile and compliance to accelerated radiotherapy plus carbogen and nicotinamide for clinical stage T2-4 laryngeal cancer: results of a phase III randomized trial.
Janssens GO; Terhaard CH; Doornaert PA; Bijl HP; van den Ende P; Chin A; Pop LA; Kaanders JH
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):532-8. PubMed ID: 21300447
[TBL] [Abstract][Full Text] [Related]
10. Accelerated radiotherapy, carbogen, and nicotinamide (ARCON) in the treatment of advanced bladder cancer: mature results of a Phase II nonrandomized study.
Hoskin P; Rojas A; Saunders M
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1425-31. PubMed ID: 19036531
[TBL] [Abstract][Full Text] [Related]
11. Expression of miR-210 in relation to other measures of hypoxia and prediction of benefit from hypoxia modification in patients with bladder cancer.
Irlam-Jones JJ; Eustace A; Denley H; Choudhury A; Harris AL; Hoskin PJ; West CM
Br J Cancer; 2016 Aug; 115(5):571-8. PubMed ID: 27441495
[TBL] [Abstract][Full Text] [Related]
12. ARCON: a novel biology-based approach in radiotherapy.
Kaanders JH; Bussink J; van der Kogel AJ
Lancet Oncol; 2002 Dec; 3(12):728-37. PubMed ID: 12473514
[TBL] [Abstract][Full Text] [Related]
13. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma.
Hoskin PJ; Rojas AM; Bentzen SM; Saunders MI
J Clin Oncol; 2010 Nov; 28(33):4912-8. PubMed ID: 20956620
[TBL] [Abstract][Full Text] [Related]
14. Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen, and nicotinamide.
Hoskin PJ; Saunders MI; Dische S
Cancer; 1999 Oct; 86(7):1322-8. PubMed ID: 10506720
[TBL] [Abstract][Full Text] [Related]
15. Improved recurrence-free survival with ARCON for anemic patients with laryngeal cancer.
Janssens GO; Rademakers SE; Terhaard CH; Doornaert PA; Bijl HP; van den Ende P; Chin A; Takes RP; de Bree R; Hoogsteen IJ; Bussink J; Span PN; Kaanders JH
Clin Cancer Res; 2014 Mar; 20(5):1345-54. PubMed ID: 24452791
[TBL] [Abstract][Full Text] [Related]
16. Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: report of European Organization for Research and Treatment of Cancer trial 22933.
Miralbell R; Mornex F; Greiner R; Bolla M; Storme G; Hulshof M; Bernier J; Denekamp J; Rojas AM; Pierart M; van Glabbeke M; Mirimanoff RO
J Clin Oncol; 1999 Oct; 17(10):3143-9. PubMed ID: 10506611
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy with carbogen breathing and nicotinamide in head and neck cancer: feasibility and toxicity.
Kaanders JH; Pop LA; Marres HA; van der Maazen RW; van der Kogel AJ; van Daal WA
Radiother Oncol; 1995 Dec; 37(3):190-8. PubMed ID: 8746587
[TBL] [Abstract][Full Text] [Related]
18. Comparison of multiple gene expression platforms for measuring a bladder cancer hypoxia signature.
Smith TAD; Lane B; More E; Valentine H; Lunj S; Abdelkarem OA; Irlam-Jones J; Shabbir R; Vora S; Denley H; Reeves KJ; Hoskin PJ; Choudhury A; West CML
Mol Med Rep; 2022 Aug; 26(2):. PubMed ID: 35730624
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of the proliferation marker Ki-67 in laryngeal carcinoma: results of the accelerated radiotherapy with carbogen breathing and nicotinamide phase III randomized trial.
Rademakers SE; Hoogsteen IJ; Rijken PF; Terhaard CH; Doornaert PA; Langendijk JA; van den Ende P; van der Kogel AJ; Bussink J; Kaanders JH
Head Neck; 2015 Feb; 37(2):171-6. PubMed ID: 24347430
[TBL] [Abstract][Full Text] [Related]
20. Acute and late morbidity in the treatment of advanced bladder carcinoma with accelerated radiotherapy, carbogen, and nicotinamide.
Hoskin PJ; Rojas AM; Phillips H; Saunders MI
Cancer; 2005 Jun; 103(11):2287-97. PubMed ID: 15834926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
